Abstract 02-microglobulin levels were determined in the serum of 18 initially asymptomatic HIV-1 p24 antigenaemic subjects who were treated with zidovudine (± acyclovir) and who were followed for 21 years. The median serum 02-microglobulin level at week 0 was 2-5 mg/l and decreased to 2-3 mgIl after 12 weeks of treatment (p = 0 001). A correlation was found between individual changes in serum f2-microglobulin levels and individual changes in serum p24 antigen levels during the first 48 weeks of treatment (p < 0 05). Six out of 18 subjects progressed to AIIDS after 60-126 weeks of treatment. In this group during a period of more than one year before disease progression median serum #2-microglobulin levels increased from 2-5 mgIl to 3-3 mg/l (p = 0-03) and median CD4 + cell counts decreased from 0 3 x 109/l to 0-08 x 109/l (p = 0-03), while in that period the pattern of serum p24 antigen levels was inconsistent. Although the variability in serum #2-microglobulin levels appeared to make this marker unsuitable for management decisions in individuals, a decline in I2-microglobulin levels was found to parallel a decline in p24 antigen levels during the early phase of zidovudine treatment. Moreover, after prolonged treatment, rising f2-microglobulin levels-in contrast to p24 antigen levels-were shown to have predictive value for disease progression.
Introduction
Treatment with the thymidine analogue zidovudine (3'-azido-3'-deoxythymidine, AZT) has been found to be of clinical benefit for patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC), and for asymptomatic subjects with human immunodeficiency virus type 1 (HIV-1) infection with less than 0 5 x 109/l circulating CD4 + cells.1-3 A temporary increase in CD4+ counts was seen in groups of zidovudinetreated subjects as opposed to a sustained decrease in groups of untreated subjects.13 Serum levels ofHIV-1 p24 antigen in zidovudine-treated subjects showed a decline in contrast with those of untreated subjects.`5 P24 antigen is a specific marker for the monitoring ofantiretroviral therapy, but it is not very sensitive: only 40-60% of patients with AIDS, and 12-25% of asymptomatic HIV-1-infected subjects have detectable circulating p24 antigen.4 8 At present the most sensitive and specific method for quantifying the in vivo antiretroviral activity appears to be the measuring ofHIV-1 titres in plasma by endpoint-dilution cultures; however, this method is too laborious for routine use.9 P2-microglobulin in a low molecular-weight polypeptide chain, present as a part of the class I major histocompatibility complex on the surface of most somatic cells.'°0 2- (+ /-2 weeks). In the subjects with disease progression to AIDS the last serum ,2-microglobulin sample measured before the moment ofdiagnosis was chosen as last evaluation point. Table 1 Serum f2-microglobulin levels, serum p24 antigen levels and CD4 + cell counts in all subjects (n = 18, week 0-48), the non-progressors (n = 12, week 0-120) and the progressors (n = 6, week 0-48); medians fig 1A, B and C.
At week 0 the median serum 2-microglobulin level in this group was 2-3 mg/l, it declined to 2-1 mg/ 1 at week 12 and it was 2 6 mg/l at week 120. A decrease was seen at week 12 (p = 0 01), and an increase at week 96 (p = 001) compared with week 0.
Disease progressors
For the six subjects who progressed to AIDS analysis was performed from week 0 until week 48 and separately at the three last evaluation points before Serum f2-microglobulin levels in asymptomatic HI V-I-infected subjects during long-term zidovudine treatment Correlations between individual changes in markers A correlation was found between individual changes in f2-microglobulin levels and individual changes in p24 antigen concentrations of the 18 subjects at weeks 12, 24 and 48 compared to week 0. The correlation coefficients were p = 0-48, p = 0-59 and p = 0-52 (p < 0-05). In the same period such a correlation was not found between individual changes in CD4 + cell counts and individual changes in P2-microglobulin levels or p24 antigen concentrations of the 18 subjects; also such a correlation was not found when the groups of non-progressors and progressors were analysed separately. These two last analyses were performed because ofthe differences in CD4 + cell counts between both groups. 
